NASDAQ: SYRE
Spyre Therapeutics Inc Stock Ownership - Who owns Spyre Therapeutics?

Insider buying vs selling

Have Spyre Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jeffrey W. AlbersDirector2024-11-066,700$36.76
$246.31kSell
Jeffrey W. AlbersDirector2024-10-25300$36.43
$10.93kSell
Scott L. BurrowsChief Financial Officer2024-09-0318,531$28.17
$522.07kSell

1 of 1

SYRE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SYRE insiders and whales buy or sell their stock.

SYRE Shareholders

What type of owners hold Spyre Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC23.70%14,301,760$224.39MInsider
Fmr LLC14.98%9,038,553$141.81MInstitution
Fairmount Funds Management LLC6.66%4,018,101$63.04MInstitution
Rtw Investments LP6.00%3,621,996$56.83MInstitution
Blackrock Inc5.92%3,572,674$56.06MInstitution
Baker Bros Advisors LP5.13%3,094,590$48.55MInsider
Vanguard Group Inc4.80%2,898,267$45.47MInstitution
Orbimed Advisors LLC4.69%2,829,748$44.40MInsider
Driehaus Capital Management LLC4.50%2,717,312$42.63MInstitution
Vr Adviser LLC4.45%2,685,448$42.13MInstitution

1 of 3

SYRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SYRE70.61%29.39%Net Selling
AVXL36.80%5.15%Net BuyingNet Buying
MLYS61.25%38.75%Net BuyingNet Selling
NRIX90.94%9.06%Net SellingNet Selling
SANA51.20%48.80%Net Selling

Spyre Therapeutics Stock Ownership FAQ

Who owns Spyre Therapeutics?

Spyre Therapeutics (NASDAQ: SYRE) is owned by 102.91% institutional shareholders, 42.83% Spyre Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Spyre Therapeutics shareholder, owning 14.30M shares representing 23.70% of the company. Fairmount Funds Management LLC's Spyre Therapeutics shares are currently valued at $224.39M.

If you're new to stock investing, here's how to buy Spyre Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.